The innovative drug concept surged in the afternoon, with Nossan hitting the 20% limit up, followed by gains in PR, Tigermed, Jiuzhou Pharma, and Highfine

The Hainan Free Trade Zone sector fluctuated and rose, with HNSS hitting the limit up and reaching a new high

The Hainan Free Trade Zone sector fluctuated and rose, with HNSS hitting the daily limit and reaching a new high, while HAIMA AUTO, HAINAN HAIYAO, HDCM, Honz, and Caesar Travel also followed suit

The traditional Chinese medicine concept continues to rise, WBDE hits the limit up, Honz, TMSP, Zhenbao Island, JI LIN AO DONG and others follow suit

Honz: Hong's investment agreement transfers 5.0004% of the company's shares

Honz announced that its controlling shareholder, Hong's Investment, has agreed to transfer 5.0004% of the company's shares at a price of RMB 5.34 per share, with a total transfer price of RMB 122 million. After the transfer is completed, Hong's Investment will hold 101 million shares of the company, accounting for 22.2534% of the company's total share capital; Beijing Chenle Asset Management Co., Ltd. - Chenle Jiaxiang No. 4 Private Securities Investment Fund will hold 22.758 million shares of the company, accounting for 5.0004% of the company's total share capital

Honz: Net loss of 54.0817 million yuan in the first half of 2025

Honz announced that in the first half of 2025, operating revenue was 232 million yuan, a year-on-year increase of 5.56%. The net loss was 54.0817 million yuan, compared to a net loss of 101 million yuan in the same period last year. The company plans not to distribute cash dividends, not to issue bonus shares, and not to convert reserves into capital